Statin use in persons with diabetes” (SUPD) was endorsed by the Pharmacy Quality Alliance (PQA) as a new performance measure in 2014 and adopted as a Centers for Medicare & Medicaid Services display measure in 2015.
The measure is based on 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, which recommend moderate- to high-intensity statin therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD) events for persons aged 40 to 75 years with diabetes.
Tier 1: lovastatin 10 mg and 20 mg*
Tier 2: lovastatin 40 mg*, pravastatin*, simvastatin*, atorvastatin**
Tier 3: Crestor**
Current information is available at Humana.com/druglistsearch.
Tiers 1 through 3 are based on 2016 Medicare and commercial formularies.
New statement: The ACC/AHA 2013 Guidelines recommend the below appropriate statin’s based on its intensity to achieve relative reductions in LDL cholesterol.
|High-intensity statin therapy Daily dose lowers LDL-C on average by 50 percent or more||Moderate-intensity statin therapy Daily dose lowers LDL-C on average by 30 to 50 percent||Low-intensity statin therapy Daily dose lowers LDL–C on average by less than 30 percent|
atorvastatin (40†) – 80 mg
rosuvastatin 20 (40) mg
atorvastatin 10 (20) mg
rosuvastatin (5) 10 mg
simvastatin 20 – 40 mg‡
pravastatin 40 (80) mg
lovastatin 40 mg
fluvastatin XL 80 mg
fluvastatin 40 mg bid
pitavastatin 2 – 4 mg
simvastatin 10 mg
pravastatin 10 – 20 mg
lovastatin 20 mg
fluvastatin 20 – 40 mg
pitavastatin 1 mg
†Evidence from one randomized controlled trial only: down-titration if unable to tolerate atorvastatin 80 mg in incremental decrease through aggressive lipid-lowering study (IDEAL).
‡Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA due to the increased risk of myopathy, including rhabdomyolysis.
To view formulary coverage for a specific drug, see Humana’s drug lists.
Our reviews show some Humana members are receiving a diabetes medication at a dose higher than the dose recommended by the U.S. Food and Drug Administration (FDA). These medications include the following categories of oral hypoglycemics: biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-IV inhibitors (DPP-IV) and sodium-glucose cotransporter inhibitors (SGLT-2).
Health care providers may receive mailings concerning these dosing recommendations:
References used to develop our communications about diabetes treatment with lipid-lowering medications and medication dosing include: